<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82238">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01826448</url>
  </required_header>
  <id_info>
    <org_study_id>PLX108-09</org_study_id>
    <nct_id>NCT01826448</nct_id>
  </id_info>
  <brief_title>A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma</brief_title>
  <official_title>A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plexxikon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Plexxikon</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the safety of an investigational new drug
      called PLX3397 when used in combination with Vemurafenib (Zelboraf™)  at different dose
      levels. Vemurafenib has been approved by the United States Food and Drug Administration
      (FDA)/European Medicines Agency (EMA) for the treatment of a specific category of
      unresectable or metastatic melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety-Subject incidence of adverse events</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjects will take oral doses of PLX3397 and vemurafenib twice a day. Physical examinations, vital signs, 12-lead electrocardiograms (ECG), adverse events, hematology and serum chemistry will be used to assess safety throughout the study. Adverse events will be monitored and reviewed for safety issues/abnormal changes in the above mentioned tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate - for those patients taking PLX3397 and vemurafenib at the recommended phase 2 dose.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will have CT scans every 6 weeks for the first 12 weeks and every 9 weeks thereafter. Response to treatment will be evaluated using RECIST 1.1 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Duration - for those patients taking PLX3397 and vemurafenib at the recommended phase 2 dose.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>CT scans will be taken every 6 weeks for the first 12 weeks and every 9 weeks thereafter. Response duration is defined as number of days from date of initial response to date of first documented disease progression or death, whichever occurs first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival (PFS)-for those patients taking PLX3397 and vemurafenib at the recommended phase 2 dose.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>CT scans will be taken every 6 weeks for the first 12 weeks and then every 9 weeks therafter. PFS will be calculated as the number of days from first day of treatment to date of first documented disease progression or date of death, whichever comes first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival- for those patients taking PLX3397 and vemurafenib at the recommended phase 2 dose.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be followed every 3 months for overall survival.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>V600-mutated BRAF Unresectable Melanoma</condition>
  <condition>V600-mutated BRAF Metastatic Melanoma</condition>
  <condition>Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor</condition>
  <arm_group>
    <arm_group_label>Dose extension cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take PLX3397 and vemurafenib at the recommended phase 2 dose.  This will be determined by the tolerability and safety of these drugs in the previous 3 cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take 1000mg/day of PLX3397 and 960mg BID of vemurafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take 800mg/day of PLX3397 and 960mg BID of vemurafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take 800mg/day of PLX3397 and 720mg BID of vemurafenib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLX3397</intervention_name>
    <arm_group_label>Dose extension cohort</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vemurafenib</intervention_name>
    <arm_group_label>Dose extension cohort</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Zelboraf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥18 years old.

          -  Patients with histologically confirmed unresectable Stage III or Stage IV metastatic
             melanoma who have not been previously treated with a selective BRAF inhibitor.

          -  Presence of a BRAF V600 mutation in the tumor tissue using the cobas BRAF mutation
             assay or comparable standard of care methodology.

          -  Measurable disease per RECIST v. 1.1 criteria.

          -  ECOG performance status 0 or 1.

        Exclusion Criteria:

          -  Radiation therapy within 14 days of C1D1.

          -  Investigational drug use within 28 days of C1D1.

          -  Patients with active CNS lesions are excluded (i.e., those with radiographically
             unstable, symptomatic lesions). However, patients treated with stereotactic therapy
             or surgery are eligible if they remain without evidence of disease progression in the
             brain for ≥3 weeks.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Henry Hsu, MD</last_name>
    <email>hhsu@plexxikon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoni Ribas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rene Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey A Sosman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kim A Margolin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Caroline Robert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dirk Schadendorf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 6, 2013</lastchanged_date>
  <firstreceived_date>April 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
